BET inhibitors have been shown to display anti-tumor activity in KRAS-driven cancers, such as pancreatic ductal adenocarcinoma and non-small cell lung cancer [4, 5]. This evidence concerns the gene DNER and pancreatic ductal adenocarcinoma.